AB Corporate Bond ETF (NASDAQ:EYEG) Stock Passes Above Fifty Day Moving Average – Here’s What Happened

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report)’s share price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $35.26 and traded as high as $35.29. AB Corporate Bond ETF shares last traded at $35.2240, with a volume of 17 shares changing hands.

AB Corporate Bond ETF Stock Up 0.4%

The business has a fifty day simple moving average of $35.26 and a 200 day simple moving average of $35.59. The firm has a market cap of $28.18 million, a price-to-earnings ratio of -20.97 and a beta of 0.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07.

Get AB Corporate Bond ETF alerts:

AB Corporate Bond ETF Increases Dividend

The company also recently announced a monthly dividend, which was paid on Thursday, June 4th. Shareholders of record on Monday, June 1st were issued a dividend of $0.1415 per share. The ex-dividend date of this dividend was Monday, June 1st. This is an increase from AB Corporate Bond ETF’s previous monthly dividend of $0.14. This represents a c) dividend on an annualized basis and a dividend yield of 4.8%. AB Corporate Bond ETF’s payout ratio is currently -102.98%.

Hedge Funds Weigh In On AB Corporate Bond ETF

A number of hedge funds have recently made changes to their positions in the company. Kestra Advisory Services LLC acquired a new position in shares of AB Corporate Bond ETF during the fourth quarter valued at approximately $34,000. Jane Street Group LLC purchased a new stake in shares of AB Corporate Bond ETF in the second quarter valued at approximately $232,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of AB Corporate Bond ETF by 32.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock valued at $5,634,000 after purchasing an additional 38,685 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

About AB Corporate Bond ETF

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Featured Stories

• Five stocks we like better than AB Corporate Bond ETF
• Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
• NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
• The World Cup Is Coming—These 3 Stocks Could Cash In
• Spotify’s “North Star” Outlook Was Music to Investors Ears

Receive News & Ratings for AB Corporate Bond ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Corporate Bond ETF and related companies with MarketBeat.com's FREE daily email newsletter.